<DOC>
	<DOC>NCT00572455</DOC>
	<brief_summary>To evaluate the safety and efficacy of PF-04217329.</brief_summary>
	<brief_title>Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<criteria>Diagnosis of primary openangle glaucoma (including pigmentary or pseudoexfoliative) or ocular hypertension in 1 or both eyes. Qualifying intraocular pressure (IOP) in the same eye at the Eligibility 1 and 2 measurements. Closed/barely open anterior chamber angle or a history of acute angle closure in either eye. Anticipate the need to initiate or modify medication (systemic or topical) that is known to affect intraocular pressure (IOP) during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Open-Angle Glaucoma</keyword>
	<keyword>Ocular Hypertension</keyword>
</DOC>